{
    "eid": "2-s2.0-85131739522",
    "title": "Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis",
    "cover-date": "2022-06-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "KRAS",
        "meta-analysis",
        "metastatic colorectal cancer",
        "survival",
        "trifluridine/tipiracil"
    ],
    "authors": [
        "T. Yoshino",
        "E. Van Cutsem",
        "J. Li",
        "L. Shen",
        "T. W. Kim",
        "V. Sriuranpong",
        "L. Xuereb",
        "P. Aubel",
        "R. Fougeray",
        "V. Cattan",
        "N. Amellal",
        "A. Ohtsu",
        "R. J. Mayer"
    ],
    "citedby-count": 5,
    "ref-count": 27,
    "ref-list": [
        "RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer",
        "ESMO consensus guidelines for the management of patients with metastatic colorectal cancer",
        "Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group",
        "KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial",
        "Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer",
        "Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer",
        "Association between specific mutations in KRAS codon 12 and colorectal liver metastasis",
        "BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients",
        "Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer: Direct and indirect comparison meta-analysis",
        "KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer",
        "2014 18 February. Review report: Lonsurf",
        "2015 16 February. Lonsurf: Prescribing information",
        "2016 16 February. Lonsurf: EPAR - Product information",
        "Randomized trial of TAS-102 for refractory metastatic colorectal cancer",
        "Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study",
        "TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial",
        "The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer",
        "PD-014 Final survival results and onset of neutropenia as an indicator of therapeutic effect in phase 2 of TAS-102 vs placebo with metastatic colorectal cancer (J003-10040030)",
        "Practical methodology of meta-analysis of individual patient data using a survival outcome",
        "Previous Releases of R for Windows. 1 April 2021. R 3.6.1 (July 2019)",
        "KRAS and BRAF mutations as prognostic and predictive biomarkers for standard chemotherapy response in metastatic colorectal cancer: a single institutional study",
        "KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer",
        "Mutations in KRAS codon 12 predict poor survival in Chinese patients with metastatic colorectal cancer",
        "Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis",
        "Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands",
        "Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis"
    ],
    "affiliation": [
        {
            "affiliation-city": "Shanghai",
            "@id": "60121918",
            "affilname": "Shanghai Dongfang Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60121918",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60068691",
            "affilname": "Asan Medical Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60068691",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Leuven",
            "@id": "60031069",
            "affilname": "KU Leuven\u2013 University Hospital Leuven",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031069",
            "affiliation-country": "Belgium"
        },
        {
            "affiliation-city": "Boston",
            "@id": "60014334",
            "affilname": "Dana-Farber Cancer Institute",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60014334",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Kashiwa",
            "@id": "60010925",
            "affilname": "National Cancer Center Hospital East",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60010925",
            "affiliation-country": "Japan"
        },
        {
            "affiliation-city": "Beijing",
            "@id": "60008510",
            "affilname": "Beijing Cancer Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008510",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Courbevoie",
            "@id": "60004412",
            "affilname": "IRIS Institut de Recherches Internationales Servier",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60004412",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Daiichi",
        "Daiichi Sankyo and Sanofi",
        "Merck Biopharma",
        "Taiho",
        "Amgen",
        "Bristol Myers Squibb",
        "Eli Lilly",
        "AstraZeneca",
        "Bayer",
        "Merck",
        "Novartis",
        "Roche",
        "Sanofi",
        "Celgene",
        "Boehringer Ingelheim",
        "Takeda",
        "Merck KGaA",
        "Merck Sharp & Dohme",
        "Pierre Fabre",
        "Astellas",
        "Servier",
        "Institut de Recherches Internationales Servier"
    ]
}